|
In line with its goal of becoming a 'discovery-led global pharmaceutical company', Dr. Reddy's has put in place state-of-the-art, fully integrated discovery infrastructure. This will go a long way in strengthening its effort to discover and develop therapeutically useful New Chemical Entities (NCEs) and market them globally.
Dr. Reddy's discovery research is conducted at:
Nearly 310 researchers are actively involved in various drug discovery and clinical development programs at these locations.
A presence in the US provides proximity to the 'thought leaders', who conceive breakthrough developments in the fundamental understanding of disease mechanisms. It also affords us a competitive advantage in gaining valuable insights into the underlying disease mechanisms. The chemistry based drug discovery strategies being developed by scientists at the Hyderabad facility, complement this pursuit of a 'target based' drug discovery approach. In addition, a synergy has been created between the two facilities in terms of developing therapeutic area expertise.
Over the past few years, we have achieved complete functional integration of the discovery infrastructure along the drug development value chain.
Our institutional capabilities span a range of areas including:
 |
Genomics and Proteomics |
|
Molecular Modeling & Drug Design |
|
Medicinal Chemistry |
|
Analytical Chemistry |
|
Pre-clinical Biology |
| |
 |
in vitro screening |
| |
|
in vivo Screening |
|
Pre-clinical Safety Evaluation |
|
Process Chemistry |
|
Drug Development |
| |
|
Clinical Pharmacology |
| |
|
Clinical Pharmacokinetics |
| |
|
Drug Metabolism |
| |
|
Pre-Formulation |
| |
|
Biostatistics and Data Management |
| |
|
Regulatory Affairs |
| |
|
Quality Assurance |
|
Project and Portfolio Management (PPM) |
|
Intellectual Property Management (IPM) |
|
Outsourcing Team |
|
